ImmunoPrecise Antibodies Ltd. (IPA), an AI-driven biotherapeutic research and technology company, announced a strategic collaboration between its subsidiary, BioStrand, and PGxAI. This partnership aims to leverage BioStrand’s patented LENSai Foundation AI Model to advance pharmacogenomics, the study of how genetic variations affect drug response.
The collaboration supports the commercial rollout of LENSai’s API by expanding its features and market reach. Pharmacogenomics is essential to IPA’s goal of creating tailored therapies and improving patient outcomes. Historically, the vast amount of genetic data has been challenging for researchers to access and interpret. LENSai addresses this by analyzing Large Language Models alongside diverse research and patient data. Recently, BioStrand made LENSai available to select partners through an API. This collaboration with PGxAI aims to enhance pharmacogenetic analysis capabilities, reflecting a shared mission of advancing healthcare through technology.
Dr. Jennifer Bath, President and CEO of IPA, stated, “Our work with PGxAI applies LENSai to a critical challenge, developing a unique pharmacogenomics AI model. With more genomic data and new insights, advanced methods are needed to predict treatment responses and adverse drug reactions. LENSai offers a groundbreaking approach to creating an adaptive AI model for predicting individual patient responses to drugs.”
Mike Zack, CEO of PGxAI, commented, “Partnering with BioStrand, a leader in AI-powered biotherapeutic solutions, aims to transform the pharmacogenomics sector and enhance the prediction of effective and safe therapies. This collaboration is a significant step toward revolutionizing personalized medicine.”
Allan Gobbs, Executive Chairman of PGxAI, added, “The clinical value of pharmacogenomics is increasingly recognized. Our model aims to personalize pharmacogenetic recommendations, potentially transforming global medication prescription practices.”
Despite advancements in AI and genomics, practical applications of precision medicine remain limited, contributing to over 30% of adverse drug reactions. By integrating pharmacogenomics with Electronic Health Records (EHRs) and AI, there is significant potential to personalize treatments and improve patient outcomes. A robust AI model in this field could revolutionize the $400 billion prescription drug market, driving innovation in precision medicine.
Dirk Van Hyfte, Head of Technology at IPA and Co-Founder of BioStrand, stated, “Deploying LENSai through API to support PGxAI’s initiatives enhances rational drug design by integrating advanced AI analysis of vast genomic data. This enables precise tailoring of therapies to individual genetic profiles, boosting treatment efficacy and safety while streamlining the drug development process. Our technology optimizes drug therapies for specific patient needs, advancing personalized medicine significantly.
